Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 317 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatitis b Virus Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics

NCT00739752
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
Non-Framed-Offered, Non-Framed-Recommended, Gain-Framed-Offered, Gain-Framed-Recommended, Loss-Framed-Offered, Loss-Framed-Recommended
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1,747 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational Results available

Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT00388674
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
entecavir, Other anti-HBV medication
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
12,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
20
States / cities
Coronado, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

NCT00644761
View directory record Official record
Conditions
Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Results available

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

NCT00524173
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir & Emtricitabine, Tenofovir
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina

NCT01544764
View directory record Official record
Conditions
Adolescent Health Services, Immunization
Interventions
Assessment , Feedback, Incentives, and eXchange Program
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

B/F/TAF Switch Study for HIV-HBV Coinfection

NCT03797014
View directory record Official record
Conditions
HIV-1-infection, Hepatitis B
Interventions
B/F/TAF
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

NCT00507689
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

NCT04449029
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, Placebo, Nucleos(t)ide therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

NCT01204762
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
pegIFN, pegIFNα-2a, PegIFN lambda, Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Anaheim, California • Garden Grove, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting No phase listed Observational

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

NCT05064553
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Interventions
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Device · Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
76
States / cities
Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

NCT03491553
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community-based Hepatitis B Interventions for Hmong Adults

NCT00888407
View directory record Official record
Conditions
Liver Cancer
Interventions
HBV Screening - Small group educational session, Nutrition - Small group educational session
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 64 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

PREHEVBRIO Pregnancy Outcomes Registry

NCT06097312
View directory record Official record
Conditions
Vaccine Exposure During Pregnancy
Interventions
Data collection
Other
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

NCT05763576
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

NCT00435825
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational

Duration of Long-term Immunity After Hepatitis B Virus Immunization

NCT01182311
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

NCT05417932
View directory record Official record
Conditions
Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma Recurrent
Interventions
SCG101
Biological
Lead sponsor
SCG Cell Therapy Pte. Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project UNITY - HIV Risk Reduction and Vaccine Education Interventions

NCT00150098
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Enhanced HIV risk reduction and HIV vaccine education
Behavioral
Lead sponsor
New York Blood Center
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

NCT01671787
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
GS-7340, Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

NCT02940496
View directory record Official record
Conditions
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7
Interventions
Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab, Ribavirin
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

NCT00395018
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Chicago, Illinois • New Orleans, Louisiana • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Results available

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

NCT02452528
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules

NCT01259453
View directory record Official record
Conditions
Hepatitis B
Interventions
Vaccination to prevent hepatitis B virus infection
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
3
States / cities
Hartford, Connecticut • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Sep 11, 2026, 8:23 AM EDT